Drug Trial Radar · NCT04856904
Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
Last checked: Nov 20, 2026Latest source record: Jun 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
121
Actual
Start
May 28, 2021
Primary completion
Feb 8, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Apr 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 17 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.
Conditions
- Acne Vulgaris
Interventions
Trifarotene CreamDrug
Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks
Trifarotene Vehicle CreamDrug
Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24Time frame: Baseline, Week 24
Locations
18 sites in 3 countries. Site status is shown where the registry gives one.
Galderma Investigational Site #8873
Scottsdale, Arizona
Galderma Investigational Site #8447
Fort Smith, Arkansas
Galderma Investigational Site #8608
Santa Monica, California
Galderma Investigational Site #9928
Boynton Beach, Florida
Galderma Investigational Site #8295
Miami, Florida
Galderma Investigational Site #8883
Miramar, Florida
Galderma Investigational Site #8189
Snellville, Georgia
Galderma Investigational Site #8367
Arlington Heights, Illinois
Galderma Investigational Site #8838
Darien, Illinois
Galderma Investigational Site #8601
Metairie, Louisiana
Galderma Investigational Site #9936
New Orleans, Louisiana
Galderma Investigational Site #8108
Las Vegas, Nevada
Galderma Investigational Site #8881
Stony Brook, New York
Galderma Investigational Site #8886
Sugarloaf, Pennsylvania
Galderma Investigational Site #9920
Arlington, Texas
Galderma Investigational Site #9918
Peterborough, Ontario, Canada
Galderma Investigational Site #9927
Saint-Jérôme, Quebec, Canada
Galderma Investigational Site #6167
Nantes, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.